Who makes BI 3000202_low dose?

BI 3000202_low dose is developed by Boehringer Ingelheim.

What development phase is BI 3000202_low dose in?

BI 3000202_low dose is in Phase 1.

Last reviewed 2026-05-15 · How we verify

BI 3000202_low dose

Boehringer Ingelheim · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	BI 3000202_low dose
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BI 3000202_low dose CI brief — competitive landscape report
BI 3000202_low dose updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI